Matthew Maurer, MD

Dr. Maurer joined Myeloid as Chief Medical Officer in November 2023. He joined Myeloid from IDEAYA Biosciences, where he was VP, Head of Medical Affairs and Clinical Oncology and participated in leading the strategy and execution of the company’s oncology portfolio and achieved clinical proof-of-concept for darovasertib, initial first-in-human testing of a MAT2A inhibitor and an IND for a PARG inhibitor in solid tumors. Prior to IDEAYA, Dr. Maurer was a senior director at Bristol Myers Squibb (BMS) where he participated in leading the early development and proof-of-concept of relatlimab in advanced melanoma as well as multiple approvals of immunotherapy combinations in renal cell carcinoma. Prior to BMS, Dr. Maurer was a physician investigator and Assistant Professor of Medicine at Columbia University College of Physicians and Surgeons, where he served as a breast cancer specialist. Dr. Maurer received a BSE in Mechanical Engineering from Princeton University and earned his medical degree from the Mount Sinai School of Medicine. Dr. Maurer is an author on over 30 peer-reviewed publications in preclinical and clinical oncology and was the principal investigator on over 15 clinical oncology trials.